| |
|
|
|
|
|
|
|||
|
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2936-2943. Prepublished online as a Blood First Edition Paper on November 28, 2006; DOI 10.1182/blood-2006-06-015461.
IMMUNOBIOLOGY Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectinmediated neutrophil rolling1 Experimental Microbiology, University Medical Center Utrecht, The Netherlands; 2 Department of Pulmonary Diseases, University Medical Center Utrecht, The Netherlands; 3 Department of Haematology, University Medical Center Utrecht, The Netherlands; 4 Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 770, Le Kremlin-Bicêtre, France; 5 Université Paris-Sud, Le Kremlin-Bicêtre, France Staphylococcus aureus secretes several virulence factors interfering with host-cell functions. Staphylococcal superantigen-like (SSL) proteins are a family of 11 exotoxins with structural homology to superantigens but with generally unknown functions. Recently, we described that chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS31-121), a potent inhibitor of C5a-induced responses, is structurally homologous to the C-terminal domain of SSL5. Here, we identify P-selectin glycoprotein ligand-1 (PSGL-1), involved in the initial rolling of neutrophils along the endothelium, as a target for SSL5. SSL5 specifically bound to Chinese hamster ovary cells stably expressing PSGL-1 (CHOPSGL-1), which was dependent of sulfation and sialylation. Furthermore, SSL5 bound to PSGL-1/Ig fusion protein immobilized on a biosensor chip. SSL5 affected binding of soluble P-selectin/Fc chimera, the principle ligand of PSGL-1, to CHOPSGL-1 cells and inhibited adhesion of neutrophils to immobilized P-selectin under static conditions. Under flow conditions SSL5 strongly decreased neutrophil rolling on immobilized P-selectin/Fc and activated human endothelial cells. In conclusion, SSL5 interferes with the interaction between PSGL-1 and P-selectin, suggesting that S aureus uses SSL5 to prevent neutrophil extravasation toward the site of infection. This makes SSL5 a potential lead for the development of new anti-inflammatory compounds for disorders characterized by excessive recruitment of leukocytes.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||